Schröder K, Finis D, Meller S, Wagenmann M, Geerling G, Pleyer U
Klinik für Augenheilkunde, Universitätsklinikum Düsseldorf, Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
Hautklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland.
Ophthalmologe. 2017 Nov;114(11):1053-1065. doi: 10.1007/s00347-017-0580-1.
Seasonal allergic conjunctivitis (SAC) is a frequent disease, which is often associated with allergic rhinitis and subsequently manifested as allergic rhinoconjunctivitis. In contrast to other types of chronic allergic conjunctivitis, the course of SAC is not sight-threatening. Pathogenetically, the underlying cause of SAC is an immunoglobulin E (IgE) mediated, Th2-driven type 1 hypersensitivity reaction. Clinically it presents with itching, light-red conjunctival injection as well as chemosis that exceeds the extent of conjunctival injection. The goals of treatment are relief of acute signs and symptoms, control of the underlying inflammatory process and utilization of preventive options. Dually effective local therapeutics combine the advantages of rapid action with a relatively long-lasting effect by a two-fold active approach. Specific immunotherapy is useful in selected patients.
季节性变应性结膜炎（SAC）是一种常见疾病，常与变应性鼻炎相关，随后表现为变应性鼻结膜炎。与其他类型的慢性变应性结膜炎不同，SAC的病程不会威胁视力。从发病机制来看，SAC的根本原因是免疫球蛋白E（IgE）介导的、Th2驱动的1型超敏反应。临床上表现为瘙痒、结膜轻度充血以及结膜水肿超过结膜充血范围。治疗目标是缓解急性体征和症状、控制潜在的炎症过程以及采用预防措施。双重有效的局部治疗药物通过双重活性方法将快速起效的优点与相对持久的效果相结合。特异性免疫疗法对部分患者有用。
